/Bio-Techne%20Corp%20sign-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Valued at a market cap of $8 billion, Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. The Minneapolis, Minnesota-based company’s products are widely used in fields like immunology, oncology, neurology, and stem cell research. It is expected to announce its fiscal Q3 earnings for 2025 before the market opens on Wednesday, May 7.
Prior to this event, analysts project this biotechnology company to report a profit of $0.45 per share, up 2.3% from $0.44 per share in the year-ago quarter. The company has a promising trajectory of consistently beating Wall Street’s bottom-line estimates in each of the last four quarters. Its adjusted earnings of $0.42 per share in the previous quarter outpaced the consensus estimates.
